Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer

Nature Genetics

Volumn 49, Issue 3, 2017, Pages 358-366

  Makohon Moore, Alvin P ^a,f   Zhang, Ming ^a   Reiter, Johannes G ^b,c   Bozic, Ivana ^c,d   Allen, Benjamin ^c,d,e   Kundu, Deepanjan ^b   Chatterjee, Krishnendu ^b   Wong, Fay ^a   Jiao, Yuchen ^a   Kohutek, Zachary A ^f   Hong, Jungeui ^f   Attiyeh, Marc ^f   Javier, Breanna ^f   Wood, Laura D ^a   Hruban, Ralph H ^a   Nowak, Martin A ^c,d   Papadopoulos, Nickolas ^a   Kinzler, Kenneth W ^a   Vogelstein, Bert ^a,g   Iacobuzio Donahue, Christine A ^f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF SCIENCE AND TECHNOLOGY AUSTRIA   (Austria)

^c HARVARD UNIVERSITY   (United States)

^d HARVARD UNIVERSITY   (United States)

^e EMMANUEL COLLEGE   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRM PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GENOMIC DNA; PROTEIN; PROTEIN P53; RETINOBLASTOMA BINDING PROTEIN 2; ROBO1 PROTEIN; SMAD4 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CASE REPORT; GENE MUTATION; GENETIC DIFFERENCE; GENETIC HETEROGENEITY; GENETIC SIMILARITY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; METASTASIS; MOLECULAR PHYLOGENY; PANCREAS ADENOCARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; WHOLE GENOME SEQUENCING; GENETICS; MUTATION; PANCREAS TUMOR;

HUMANS; MUTATION; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS;

EID: 85009726777     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3764     Document Type: Article

References (60)

1. Greaves, M. & Maley, C.C. Clonal evolution in cancer. Nature 481, 306-313 (2012).
2. Alizadeh, A.A. et al. Toward understanding and exploiting tumor heterogeneity. Nat. Med. 21, 846-853 (2015).
3. Yates, L.R. et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat. Med. 21, 751-759 (2015).
4. Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225-233 (2014).
5. de Bruin, E.C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251-256 (2014).
6. Zhang, J. et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346, 256-259 (2014).
7. Gundem, G. et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520, 353-357 (2015).
8. Hong, M.K.H. et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat. Commun. 6, 6605 (2015).
9. Kumar, A. et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat. Med. 22, 369-378 (2016).
10. Jones, S. et al. Comparative lesion sequencing provides insights into tumor evolution. Proc. Natl. Acad. Sci. USA 105, 4283-4288 (2008).
11. Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117 (2010).
12. Campbell, P.J. et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109-1113 (2010).
13. Sanborn, J.Z. et al. Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proc. Natl. Acad. Sci. USA 112, 10995-11000 (2015).
14. Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90-94 (2011).
15. Tomasetti, C., Vogelstein, B. & Parmigiani, G. Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proc. Natl. Acad. Sci. USA 110, 1999-2004 (2013).
16. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).
17. Makohon-Moore, A. & Iacobuzio-Donahue, C.A. Pancreatic cancer biology and genetics from an evolutionary perspective. Nat. Rev. Cancer 16, 553-565 (2016).
18. Barber, L.J. et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J. Pathol. 229, 422-429 (2013).
19. Diaz, L.A. Jr. et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537-540 (2012).
20. Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532-536 (2012).
21. Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495-501 (2015).
22. Hoogstraat, M. et al. Genomic and transcriptomic plasticity in treatment-naive ovarian cancer. Genome Res. 24, 200-211 (2014).
23. Krasnitz, A., Sun, G., Andrews, P. & Wigler, M. Target inference from collections of genomic intervals. Proc. Natl. Acad. Sci. USA 110, E2271-E2278 (2013).
24. Davoli, T. et al. Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell 155, 948-962 (2013).
25. Siegel, R.L., Miller, K.D. & Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 66, 7-30 (2016).
26. Embuscado, E.E. et al. Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol. Ther. 4, 548-554 (2005).
27. Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47-52 (2016).
28. Chang, M.T. et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat. Biotechnol. 34, 155-163 (2016).
29. Douville, C. et al. CRAVAT: cancer-related analysis of variants toolkit. Bioinformatics 29, 647-648 (2013).
30. Iacobuzio-Donahue, C.A., Velculescu, V.E., Wolfgang, C.L. & Hruban, R.H. Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. Clin. Cancer Res. 18, 4257-4265 (2012).
31. Borazanci, E. et al. Adenosquamous carcinoma of the pancreas: molecular characterization of 23 patients along with a literature review. World J. Gastrointest. Oncol. 7, 132-140 (2015).
32. Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K.W. & Vogelstein, B. Detection and quantification of rare mutations with massively parallel sequencing. Proc. Natl. Acad. Sci. USA 108, 9530-9535 (2011).
33. Yachida, S. & Iacobuzio-Donahue, C.A. The pathology and genetics of metastatic pancreatic cancer. Arch. Pathol. Lab. Med. 133, 413-422 (2009).
34. Olive, K.P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461 (2009).
35. Campbell, P.J. et al. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc. Natl. Acad. Sci. USA 105, 13081-13086 (2008).
36. Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806 (2008).
37. Biankin, A.V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399-405 (2012).
38. Schutte, M. et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 57, 3126-3130 (1997).
39. Santarius, T., Shipley, J., Brewer, D., Stratton, M.R. & Cooper, C.S. A census of amplified and overexpressed human cancer genes. Nat. Rev. Cancer 10, 59-64 (2010).
40. Maley, C.C. et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 38, 468-473 (2006).
41. Fernández, L.C., Torres, M. & Real, F.X. Somatic mosaicism: on the road to cancer. Nat. Rev. Cancer 16, 43-55 (2016).
42. Blokzijl, F. et al. Tissue-specific mutation accumulation in human adult stem cells during life. Nature 538, 260-264 (2016).
43. Reiter, J.G. et al. Reconstructing metastatic seeding patterns of human cancers. Nat. Commun. http://dx.doi.org/10.1038/ncomms14114 (2017).
44. Sottoriva, A. et al. A Big Bang model of human colorectal tumor growth. Nat. Genet. 47, 209-216 (2015).
45. Waclaw, B. et al. A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity. Nature 525, 261-264 (2015).
46. Maddipati, R. & Stanger, B.Z. Pancreatic cancer metastases harbor evidence of polyclonality. Cancer Discov. 5, 1086-1097 (2015).
47. Gibson, W.J. et al. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nat. Genet. 48, 848-855 (2016).
48. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
49. Jones, P.A. & Baylin, S.B. The epigenomics of cancer. Cell 128, 683-692 (2007).
50. Williams, M.J., Werner, B., Barnes, C.P., Graham, T.A. & Sottoriva, A. Identification of neutral tumor evolution across cancer types. Nat. Genet. 48, 238-244 (2016).
51. Bozic, I., Gerold, J.M. & Nowak, M.A. Quantifying clonal and subclonal passenger mutations in cancer evolution. PLoS Comput. Biol. 12, e1004731 (2016).
52. Witkiewicz, A.K. et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun. 6, 6744 (2015).
53. Jiao, Y. et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat. Genet. 45, 1470-1473 (2013).
54. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J.R. Stat. Soc. 57, 289-300 (1995).
55. Salari, R. et al. Inference of tumor phylogenies with improved somatic mutation discovery. J. Comput. Biol. 20, 933-944 (2013).
56. El-Kebir, M., Oesper, L., Acheson-Field, H. & Raphael, B.J. Reconstruction of clonal trees and tumor composition from multi-sample sequencing data. Bioinformatics 31, i62-i70 (2015).
57. Popic, V. et al. Fast and scalable inference of multi-sample cancer lineages. Genome Biol. 16, 91 (2015).
58. Boeva, V. et al. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics 28, 423-425 (2012).
59. Krzywinski, M. et al. Circos: an information aesthetic for comparative genomics. Genome Res. 19, 1639-1645 (2009).
60. Lappalainen, I. et al. The European Genome-phenome Archive of human data consented for biomedical research. Nat. Genet. 47, 692-695 (2015).